YK11 |
| Catalog No.GC31442 |
A partial agonist of the androgen receptor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1370003-76-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
YK11 is a partial agonist of androgen receptor, with osteogenic activity.
YK11 is a partial agonist of androgen receptor, and induces myogenic differentiation of C2C12 Cells at 500 nM via Fst mRNA upregulation by AR. YK11 enhances Myf5 and myogenin mRNA expression, but requires high concentrations (YK11, 100 nM or 500 nM)[1]. YK11 (0.5 µM) increases the cell growth of osteoblastic MC3T3-E1 cells, and enhances ALP activity via AR. YK11 also elevates osteoprotegerin mRNA expression (0.5 µM) and dose-dependently increases osteocalcin mRNA expression (0.1-1.0 µM). In addition, YK11 enhances phosphorylation of Akt protein via rapid non-genomic signaling[2].
[1]. Kanno Y, et al. Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biol Pharm Bull. 2013;36(9):1460-5. [2]. Yatsu T, et al. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells. Biol Pharm Bull. 2018;41(3):394-398.
Average Rating: 5 (Based on Reviews and 40 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *